In the past twenty-three years, 15,277 cases of erysipelas were admitted to the isolation pavilion of Bellevue Hospital. During that time almost every conceivable form of treatment was practiced, most of it based on the application of local remedies. None of them appeared appreciably to shorten the course of the disease—and erysipelas, although commonly regarded as a self-limited process, seldom, in our experience at least, brings itself to an abrupt end, but is apt to pursue a leisurely course, sometimes consuming weeks. Within the past year, Birkhaug1 introduced the antitoxin treatment of erysipelas, employing it in a series of sixty cases with results that were astonishing. In Bellevue Hospital, which maintains, perhaps, the largest and most active erysipelas service in the world, we are now using the antitoxin treatment to the exclusion of other methods. As our first trial, we employed an unconcentrated product provided gratuitiously by the Lederle
SYMMERS D, LEWIS KM. THE ANTITOXIN TREATMENT OF ERYSIPELAS: OBSERVATIONS IN ONE HUNDRED AND THIRTY-ONE PATIENTS AT BELLEVUE HOSPITAL. JAMA. 1927;89(11):880–882. doi:10.1001/jama.1927.02690110044015
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: